Stoke Therapeutics Inc expected to post a loss of 56 cents a share - Earnings Preview

Stoke Therapeutics

02/08/2024 17:17

* Stoke Therapeutics Inc  STOK.OQ   STOK.O  is expected
to show a
rise in quarterly revenue when it reports  results on August 5
(estimated) for the period ending June 30 2024
    * The Bedford Massachusetts-based  company is expected to
report a
231.2% decrease in revenue to $3.256 million from $-2.48 million
a year ago, according to the mean estimate from 9 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Stoke Therapeutics Inc
is for
a loss of 56 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Stoke
Therapeutics Inc is $21.00​, above​ its last closing price
of $14.72. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.61       -0.61      -0.57     Beat    6.6
 Dec. 31 2024  -0.48       -0.63      -0.60     Beat    4.8
 Sep. 30 2023  -0.64       -0.63      -0.55     Beat    12.4​
 Jan. 1 0001   -0.62       -0.64      -0.69     Missed  -8.4
 ​​Jan.        -0.68       -0.70      -0.53     Beat    23.9
 1 0001                                                 
 Jan. 1 0001   -0.70       -0.70      -0.65     Beat    3.5​
 Sep. 30 2022  -0.68       -0.68      -0.66     Beat    3.5
 Jun. 30 2022  -0.69       -0.69      -0.63     Beat    8.4
 This summary was machine generated August 2 at 16:16 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)